β¨ Medicines and Tax Ruling Notices
17 JANUARY 2008
NEW ZEALAND GAZETTE, No. 6
Product:
Apo-Risperidone
Active Ingredient:
Risperidone 3mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Apotex NZ Limited
Manufacturer:
Apotex Inc, Weston, Ontario, Canada
Product:
Apo-Risperidone
Active Ingredient:
Risperidone 4mg
Dosage Form:
Film coated tablet
New Zealand Sponsor:
Apotex NZ Limited
Manufacturer:
Apotex Inc, Weston, Ontario, Canada
Product:
Apo-Topiramate
Active Ingredient:
Topiramate 100mg
Dosage Form:
Tablet
New Zealand Sponsor:
Apotex NZ Limited
Manufacturer:
Apotex Inc, Etobicoke, Ontario, Canada
Product:
Apo-Topiramate
Active Ingredient:
Topiramate 200mg
Dosage Form:
Tablet
New Zealand Sponsor:
Apotex NZ Limited
Manufacturer:
Apotex Inc, Etobicoke, Ontario, Canada
Product:
Apo-Topiramate
Active Ingredient:
Topiramate 25mg
Dosage Form:
Tablet
New Zealand Sponsor:
Apotex NZ Limited
Manufacturer:
Apotex Inc, Etobicoke, Ontario, Canada
Product:
Apo-Topiramate
Active Ingredient:
Topiramate 50mg
Dosage Form:
Tablet
New Zealand Sponsor:
Apotex NZ Limited
Manufacturer:
Apotex Inc, Etobicoke, Ontario, Canada
185
Product:
Panadol Sinus Relief PE
Active Ingredients:
Paracetamol 500mg
Phenylephrine hydrochloride 5mg
Dosage Form:
Tablet
New Zealand Sponsor:
GlaxoSmithKline (NZ) Limited
Manufacturer:
GlaxoSmithKline Australia Pty Limited, Consumer Healthcare, Ermington, New South Wales, Australia
Product:
Siterone
Active Ingredient:
Cyproterone acetate 100mg
Dosage Form:
Tablet
New Zealand Sponsor:
REX Medical Limited
Manufacturer:
Cipla Limited, Salcette, Goa, India
Dated this 14th day of January 2008.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
go289
Inland Revenue
Tax Administration Act 1994
Notice of Product Ruling
-
This is a notice of a product ruling made under section 91F of the Tax Administration Act 1994.
-
Product ruling No. 07/05 was issued on 18 October 2007. It relates to the application of various provisions of the Income Tax Act 2004 to the operation of the Tortis-International Fund. It will appear in Inland Revenueβs Tax Information Bulletin, Vol. 20, No. 1, February 2008.
-
A copy of the ruling may be obtained by writing to the Team Manager (Technical Services), Office of the Chief Tax Counsel, National Office, Inland Revenue, PO Box 2198, Wellington.
GARY DICK, Team Manager (Technical Services), Office of the Chief Tax Counsel.
go287
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2008, No 6
Gazette.govt.nz —
NZ Gazette 2008, No 6
β¨ LLM interpretation of page content
π₯
Consent to Distribution of New Medicines
(continued from previous page)
π₯ Health & Social Welfare14 January 2008
Medicines, Distribution, Risperidone, Topiramate, Panadol Sinus Relief PE, Siterone
- JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate
π° Notice of Product Ruling
π° Finance & RevenueTax Administration Act, Product Ruling, Tortis-International Fund, Income Tax Act
- GARY DICK, Team Manager (Technical Services), Office of the Chief Tax Counsel